Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 1;50(43):9399-408.
doi: 10.1021/bi201173d. Epub 2011 Oct 7.

Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant

Affiliations

Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant

Min Liu et al. Biochemistry. .

Abstract

Leucine-rich repeat kinase 2 (LRRK2), a large and complex protein that possesses two enzymatic properties, kinase and GTPase, is one of the major genetic factors in Parkinson's disease (PD). Here, we characterize the kinetic and catalytic mechanisms of truncated wild-type (t-wt) LRRK2 and its most common mutant, G2019S (t-G2019S), with a structural interpretation of the kinase domain. First, the substitution of threonine with serine in the LRRKtide peptide results in a much less efficient substrate as demonstrated by a 26-fold decrease in k(cat) and a 6-fold decrease in binding affinity. The significant decrease in k(cat) is attributed to a slow chemical transfer step as evidenced by the inverse solvent kinetic isotope effect in the proton inventory and pL (pH or pD)-dependent studies. The shape of the proton inventory and pL profile clearly signals the involvement of a general base (pK(a) = 7.5) in the catalysis with a low fractionation factor in the ground state. We report for the first time that the increased kinase activity of the G2019S mutant is substrate-dependent. Homology modeling of the kinase domain (open and closed forms) and structural analysis of the docked peptide substrates suggest that electrostatic interactions play an important role in substrate recognition, which is affected by G2019S and may directly influence the kinetic properties of the enzyme. Finally, the GTPase activity of the t-G2019S mutant was characterized, and the mutation modestly decreases GTPase activity without significantly affecting GTP binding affinity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Steady-state kinetic studies of LRRK2-catalyzed phosphorylation. (A) Phosphorylation of LRRKtide by t-wt LRRK2 (○) and the mutant t-G2019S (●). (B) Phosphorylation of LRRKtideS by t-wt LRRK2 (●) and the mutant t-G2019S (○). (C) Phosphorylation of PLK-peptide by t-wt LRRK2 (●) and the mutant t-G2019S (○). (D) Structural details of peptide binding (LRRKtide on the top-left and PLK-peptide on the top-right) near the ATP binding site of LRRK2. Both peptides show a series of conserved interactions involving residues such as D1887 and R1915. In case of LRRKtide, R14 makes hydrogen bonds with ATP as well as D2017 (DGY loop) of LRRK2. The structural equivalent position in PLK-peptide is occupied by L6 and does not participate in hydrogen bonding with ATP or D2017. This suggests that LRRKtide is likely to be more sensitive to mutations in the DYG-loop region compared to PLK-peptide. In the bottom-left panel, the interaction of LRRKtideS with the active site of LRRK2 is shown in details. S12 of LRRKtideS is in close proximity of charged residues including D2017 and D1994. In the bottom right-panel, the interaction of LRRKtide (contains Thr instead of Ser) with the active site of LRRK2 is shown in detail. The methyl group of T12 is placed between the oxygen of T12 and D1994 leading to charge shielding in this region.
Figure 2
Figure 2
Isotope exchange analysis for the mutant t-G2019S-catalyzed LRRKtide phosphorylation. Effect of [ADP]/[ATP] (A), [PO4-LRRKtide]/[LRRKtide] (B), [ADP]/[LRRKtide] (C), and [PO4-LRRKtide]/[ATP] (D) concentrations on the initial rates of the ATP to PO4-LRRKtide isotopic exchanges. The concentrations of the varied reactants were maintained at a constant ratio of 20 while the other reactants were kept as 1 and 20 µM for the substrate and product, respectively. The trace amount of radioactive ATP was added prior to the initiation of the reaction by the addition of enzyme. The data in panel A and B were fit to the simple Michaelis-Menton equation, and data in panel C and D were fit to the equation reflecting the substrate inhibition: v = vmaxS/(Km + [S](1 + [S]/Ki)).
Figure 3
Figure 3
Proton inventory and pL-dependent studies for t-wt LRRK2-catalyzed LRRKtide phosphorylaiton. For the proton inventory study, the initial velocities were measured at saturating concentrations of both ATP and peptide substrates for kcat in the mixture of H2O and D2O at pH 8.2 and pD equivalent. The dependence of the ratio of kcat (kn/k0) in the presence and absence of varying atom fractions of D2O (n) on n revealed a normal SKIE of 1.1 (A). pL-dependent studies were carried out using a triple buffer consisting of 50 mM MES, 100 mM Tris, and 50 mM acetic acid. Panel B revealed pH (●) and pD (○) dependencies of kcat with a SKIE of 1.1 and panel C revealed pH (●) and pD (○) dependencies of kcat/Km with a SKIE of 1.2.
Figure 4
Figure 4
Proton inventory and pL-dependent studies for t-wt LRRK2-catalyzed LRRKtideS phosphorylation. Panel A shows proton inventory studies of LRRKtideS phosphorylation. The inset shows the reciprocal of the ratio of kcat (k0/kn) dependence on n. Panel B reveals pH (●) and pD (○) dependencies of kcat with a SKIE of 0.65 and panel C reveals pH (●) and pD (○) dependencies of kcat/Km with a SKIE of 0.57.
Figure 5
Figure 5
LRRK2-catalyzed GTP hydrolysis. Initial velocities were measured as a function of [GTP] for t-wt LRRK2 (○) and the mutant t-G2019S (●).

References

    1. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. 2005;28:57–87. - PubMed
    1. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595–600. - PubMed
    1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607. - PubMed
    1. Berg D, Schweitzer KJ, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T, Wszolek ZK, Gasser T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain. 2005;128:3000–3011. - PubMed
    1. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005;128:2786–2796. - PubMed

Publication types

Substances